128 related articles for article (PubMed ID: 37592047)
41. Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.
Weycker D; Li X; Barron R; Wu H; Morrow PK; Xu H; Reiner M; Garcia J; Mhatre SK; Lyman GH
J Natl Compr Canc Netw; 2015 Aug; 13(8):979-86. PubMed ID: 26285243
[TBL] [Abstract][Full Text] [Related]
42. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.
Schelenz S; Giles D; Abdallah S
Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152
[TBL] [Abstract][Full Text] [Related]
43. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
44. Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis.
Zhu X; Zhang W; Zhang Y; Wang Y; Hu H; Li J; Zhou Y; Han T; Huang D
Hematology; 2023 Dec; 28(1):2172292. PubMed ID: 36719297
[TBL] [Abstract][Full Text] [Related]
45. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
46. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
47. Febrile Neutropenia Syndromes in Children: Risk Factors and Outcomes of Primary, Prolonged, and Recurrent Fever.
Alali M; David MZ; Ham SA; Danziger-Isakov L; Pisano J
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e962-e971. PubMed ID: 34133386
[TBL] [Abstract][Full Text] [Related]
48. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.
Teuffel O; Amir E; Alibhai S; Beyene J; Sung L
Br J Cancer; 2011 Apr; 104(9):1377-83. PubMed ID: 21468048
[TBL] [Abstract][Full Text] [Related]
49. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Kuderer NM; Dale DC; Crawford J; Cosler LE; Lyman GH
Cancer; 2006 May; 106(10):2258-66. PubMed ID: 16575919
[TBL] [Abstract][Full Text] [Related]
50. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
51. Absolute Monocyte Count as Early and Safe Marker for Antibiotic Cessation in Febrile Neutropenia Without Etiology in Pediatric Oncology Patients.
Alali M; Prather C; Danziger-Isakov LA; Kussin ML; Khalifeh M; Al Othman N; Bartlett AH
J Pediatr Hematol Oncol; 2023 Aug; 45(6):e702-e709. PubMed ID: 37494607
[TBL] [Abstract][Full Text] [Related]
52. Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units.
Penel-Page M; Marec-Bérard P; Morelle M; Bertrand A; Riberon C; Boyle H; Perrier L
J Adolesc Young Adult Oncol; 2017 Dec; 6(4):542-550. PubMed ID: 28678005
[TBL] [Abstract][Full Text] [Related]
53. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
54. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
56. The role of proangiogenic cytokines in predicting sepsis in febrile neutropenic children with cancer.
Çakmakcı S; Sarı N; Sönmez Ç; İlhan İE
Turk J Pediatr; 2024; 66(1):90-98. PubMed ID: 38523383
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas.
Wang XJ; Tong WX; Chan A
Clin Ther; 2017 Jun; 39(6):1161-1170. PubMed ID: 28554533
[TBL] [Abstract][Full Text] [Related]
58. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.
Stern A; Carrara E; Bitterman R; Yahav D; Leibovici L; Paul M
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012184. PubMed ID: 30605229
[TBL] [Abstract][Full Text] [Related]
59. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
[TBL] [Abstract][Full Text] [Related]
60. Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents.
Crothers A; Haeusler GM; Slavin MA; Babl FE; Mechinaud F; Phillips R; Tapp H; Padhye B; Zeigler D; Clark J; Walwyn T; Super L; Alvaro F; Thursky K; De Abreu Lourenco R
EClinicalMedicine; 2021 Oct; 40():101095. PubMed ID: 34746716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
